CNS tumors: Monitoring therapeutic response and outcome prediction

Topics in Magnetic Resonance Imaging

Volumn 17, Issue 2, 2006, Pages 63-68

  Cha, Soonmee ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain tumors; MRI; Treatment outcome

Indexed keywords

ANTINEOPLASTIC AGENT; DEUTERIUM OXIDE; GADOLINIUM PENTETATE; TRACER;

BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; HUMAN; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

CENTRAL NERVOUS SYSTEM NEOPLASMS; HUMANS; PROGNOSIS; TREATMENT OUTCOME;

EID: 33846027468     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/RMR.0b013e31802ee598     Document Type: Review

References (32)

1. Burger PC, Vogel FS. The brain: tumors. In: Burger PC, Vogel FS, eds. Surgical Pathology of the Central Nervous System and Its Coverings. New York: Wiley; 1982:223-266.
2. Burger PC, Vogel FS, Green SB, et al. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer. 1985;56:1106-1111.
3. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer. 2000;88:2887.
4. Kleihues P, Ohgaki H. Phenotype vs genotype in the evolution of astrocytic brain tumors. Toxicol Pathol. 2000;28:164-170.
5. Avgeropoulos NG, Batchelor TT. New treatment strategies for malignant gliomas. Oncologist. 1999;4:209-224.
6. Kirsch M, Schackert G, Black PM. Anti-angiogenic treatment strategies for malignant brain tumors. J Neurooncol. 2000;50:149-163.
7. Newton HB. Novel chemotherapeutic agents for the treatment of brain cancer. Expert Opin Investig Drugs. 2000;9:2815-2829.
8. Schiff D. Single brain metastasis. Curr Treat Options Neurol. 2001;3:89-99.
9. Prados MD, Levin V. Biology and treatment of malignant glioma. Semin Oncol. 2000;27:1-10.
10. Lopez KA, Waziri AE, Canoll PD, et al. Convection-enhanced delivery in the treatment of malignant glioma. Neurol Res. 2006;28:542-548.
11. Hall WA, Sherr GT. Convection-enhanced delivery: targeted toxin treatment of malignant glioma. Neurosurg Focus. 2006;20:E10.
12. Lidar Z, Mardor Y, Jonas T, et al. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg. 2004;100:472-479.
13. Dillon WP. Imaging of central nervous system tumors. Curr Opin Radiol. 1991;3:46-50.
14. Felix R, Schorner W, Laniado M, et al. Brain tumors: MR imaging with gadolinium-DTPA. Radiology. 1985;156:681-688.
15. Mardor Y, Pfeffer R, Spiegelmann R, et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol. 2003;21:1094-1100.
16. Hamstra DA, Chenevert TL, Moffat BA, et al. Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A. 2005;102:16759-16764.
17. Zierler KL. Circulation times and the theory of indicator-dilution methods for determining blood flow and volume. In: Handbook of Physiology. Baltimore: Williams & Wilkins; 1962:585-615.
18. Rosen BR, Belliveau JW, Vevea JM, et al. Perfusion imaging with NMR contrast agents. Magn Res Med. 1990;14:249-265.
19. Villringer A, Rosen BR, Belliveau JW, et al. Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects. Magn Reson Med. 1988;6:164-174.
20. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. I. Fundamental concepts. Magn Reson Med. 1991;17:357-367.
21. Patankar TF, Haroon HA, Mills SJ, et al. Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas? AJNR Am J Neuroradiol. 2005;26:2455-2465.
22. Roberts HC, Roberts TP, Brasch RC, et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol. 2000;21:891-899.
23. Tofts PS, Brix G, Buckly DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223-232.
24. Harrer JU, Parker GJ, Haroon HA, et al. Comparative study of methods for determining vascular permeability and blood volume in human gliomas. J Magn Reson Imaging. 2004;20:748-757.
25. Mayr NA, Yuh WT, Magnotta VA, et al. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int J Radiat Oncol Biol Phys. 1996;36:623-633.
26. Knopp MV, Brix G, Junkermann HJ, et al. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. Magn Reson Imaging Clin N Am. 1994;2:633-658.
27. Valk PE, Dillon WP. Radiation injury of the brain. AJNR Am J Neuroradiol. 1991;12:45-62.
28. Ricci PE, Karis JP, Heiserman JE, et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR Am J Neuroradiol. 1998;19:407-413. see comments.
29. Thompson TP, Lunsford LD, Kondziolka D. Distinguishing recurrent tumor and radiation necrosis with positron emission tomography versus stereotactic biopsy. Stereotact Funct Neurosurg. 1999;73:9-14.
30. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190-198.
31. Pierallini A, Bonamini M, Bozzao A, et al. Supratentorial diffuse astrocytic tumours: proposal of an MRI classification. Eur Radiol. 1997;7:395-399.
32. Pope WB, Sayre J, Perlina A, et al. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005;26:2466-2474.